Capital Asset Advisory Services LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 331.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,140 shares of the company’s stock after purchasing an additional 8,560 shares during the period. Capital Asset Advisory Services LLC’s holdings in Johnson & Johnson were worth $1,693,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Kessler Investment Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $29,000. Exchange Traded Concepts LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $31,000. University of Texas Texas AM Investment Managment Co. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $31,000. Permanens Capital L.P. boosted its position in shares of Johnson & Johnson by 33.3% during the third quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after buying an additional 100 shares during the period. Finally, Clear Investment Research LLC boosted its position in shares of Johnson & Johnson by 23.1% during the fourth quarter. Clear Investment Research LLC now owns 539 shares of the company’s stock worth $79,000 after buying an additional 101 shares during the period. 69.60% of the stock is owned by institutional investors and hedge funds.
JNJ opened at $131.80 on Thursday. Johnson & Johnson has a 52-week low of $126.10 and a 52-week high of $154.50. The firm has a market capitalization of $373.41 billion, a PE ratio of 19.44, a PEG ratio of 2.36 and a beta of 0.74. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.01 and a current ratio of 1.26. The business’s 50-day simple moving average is $146.91 and its 200 day simple moving average is $138.46.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.01. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The business had revenue of $20.75 billion for the quarter, compared to analyst estimates of $20.83 billion. During the same quarter in the prior year, the company posted $1.97 earnings per share. Johnson & Johnson’s revenue was up 1.7% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 9.03 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th were issued a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.88%. Johnson & Johnson’s payout ratio is presently 43.78%.
Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reaffirmed a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Citigroup began coverage on Johnson & Johnson in a research report on Wednesday, March 4th. They set a “buy” rating and a $163.00 price objective for the company. Morgan Stanley raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $145.00 to $170.00 in a research report on Tuesday, December 17th. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $173.00 in a research report on Thursday, December 19th. Finally, Raymond James upped their price objective on Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research report on Thursday, January 23rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and an average target price of $162.33.
In other Johnson & Johnson news, COO Michael E. Sneed sold 58,128 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total value of $8,683,741.92. Following the sale, the chief operating officer now owns 107,511 shares in the company, valued at $16,061,068.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Hubert Joly acquired 5,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What does EPS mean?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.